Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: J Immunol. 2011 Mar 23;186(9):5489–5496. doi: 10.4049/jimmunol.1001623

Figure 4.

Figure 4

Inhibition of JNK Kinase and Akt pathways block IL-1β mRNA splicing in human platelets. Platelets were treated with or without LPS, soluble CD14, and LPS-binding protein for 3 hours and IL-1β splicing determined by real-time quantitative PCR as in Figure 2. The JNK inhibitor, SP600125 (500 nM), inhibits IL-1β splicing (A). An inhibitor of Akt (1.5 uM), also inhibits splicing (B). Error bars = +/− 1 SE, N=3.